The aryl hydrocarbon receptor (AHR) is a ligandactivated transcription factor that triggers a broad response, which includes the regulation of proinflammatory cytokine production by monocytes and macrophages. AHR is negatively regulated by a set of genes that it transcriptionally activates, including the AHR repressor (Ahrr) and the cytochrome P450 1 (Cyp1) family, which are critical for preventing exacerbated AHR activity. An imbalance in these regulatory mechanisms has been shown to cause severe defects in lymphoid cells. Therefore, we wanted to assess how AHR activation is regulated in monocytes and macrophages in the context of innate immune responses induced by pathogenassociated molecular patterns (PAMPs). We found that concomitant stimulation of primary human monocytes with PAMPs and the AHR agonist 6-formylindolo(3,2-b) carbazole (FICZ) led to a selective dose-dependent inhibition of Cyp1 family members induction. Two other AHR-dependent genes [Ahrr and NADPH quinone dehydrogenase 1 (Nqo1)] were not affected under these conditions, suggesting a split in the AHR regulation by PAMPs. This down-regulation of Cyp1 family members did not require de novo protein production nor signaling through p38, ERK, or PI3K-Akt-mammalian target of rapamycin (mTOR) pathways. Furthermore, such a split regulation of the AHR response was more apparent in GM-CSF-derived macrophages, a finding corroborated at the functional level by decreased CYP1 activity and decreased proinflammatory cytokine production in response to FICZ and LPS. Collectively, our findings identify a role for pattern recognition receptor (PRR) signaling in regulating the AHR response through selective downregulation of Cyp1 expression in human monocytes and macrophages.
Introduction
The AHR is a ligand-activated transcription factor, initially identified as the receptor mediating the toxic effects of TCDD [1] . Its ligands are certain polycyclic aromatic compounds, including TCDD and FICZ, as well as tryptophan metabolites, such as KYN and indoles [2] . In homeostasis, AHR is predominately found in the cytoplasm tethered to the cytoskeleton by an inactivation complex that includes heat shock protein-90 [3, 4] , the AHR-interacting protein [5, 6] , and p23 [7] . Following ligand binding, AHR dissociates from the cytoskeleton, sheds the majority of its inactivation complex, and translocates into the nucleus in a b-importindependent mechanism [8] . In the nucleus, AHR dimerizes with its DNA-binding partner ARNT (also known as hypoxiainducible factor 1b) [9, 10] and transcriptionally activates a set of genes, collectively known as the AHR gene battery. The best characterized AHR gene-battery members are the Cyp1 family (Cyp1a1, Cyp1a2, and Cyp1b1) and Ahrr but may also include other genes, such as Fmo3, Nqo1, Npxt1, Tiparp, and Ugt1a6 [11] .
Critical for an AHR response is the ability to turn off the signal when it is no longer required. The problem of having enhanced or prolonged AHR activation is best exemplified by the toxicity of TCDD, a contaminant in Agent Orange that causes birth defects in children and other health problems as a result of its high resistance to metabolism by CYP1 [1] . AHR signaling can be turned off by 3 mechanisms: 1) proteasome degradation following nuclear export and ubiquitination [12, 13] , 2) disruption of AHR-ARNT dimers by AHRR [14] , and 3) metabolism of ligands by CYP1 [15] and other enzymes [16] . With regard to this last mechanism, it has been reported that the inhibition of CYP1 in keratinocytes was sufficient to prolong AHR activation and preserve extracellular ligand concentrations [17] . It has also been observed that Cyp1-deficient zebrafish treated with FICZ had developmental defects similar to those caused by TCDD [18] . Moreover, some molecules initially described as AHR ligands were later determined to be antagonists of CYP1 [17] .
In addition to its role in clearing dioxins, AHR is an effective regulator of the development and function of the immune system [19] . AHR activation can enhance Th17 or T reg differentiation and augment or protect against experimental autoimmune encephalitis, respectively [20, 21] . AHR can also regulate innate immunity by controlling proinflammatory responses in both macrophages [22] and DCs [23] . In macrophages, AHR activation limits the production of proinflammatory cytokines (e.g., IL-6, IL-12p70, and TNF-a) by blocking the NF-kB-dependent transcription through a mechanism that involves STAT1 [22] . Interestingly, this regulation was not observed for the anti-inflammatory cytokine IL-10, despite NF-kB signaling, at least partially regulating its transcription [24] . The significance of these findings is that AHR is involved in the mechanism of endotoxin tolerance and could protect against subsequent infections [25] . Moreover, it was recently shown that AHR can regulate antiviral responses and type I IFN production by blocking TNF receptor-associated factor family memberassociated NF-kB activator-binding kinase 1activity through its target gene TiPARP [26] . Collectively, these findings highlight the impact of AHR and its ligands on the development of an innate immune response.
The implications of the negative feedback regulators of AHR signaling on the development and progression of an immune response are beginning to gain attention. For example, it was recently reported that the AHRR is highly expressed in barrier immune cells and works in concert with AHR to decrease inflammation at these sites [27] . In contrast, during systemic inflammation, the AHRR augments the hyperinflammatory state in endotoxin shock, likely through blocking AHR and causing enhanced NF-kB signaling. Likewise, transgenic overexpression of AHRR in mice also protects against acute TCDD toxicity by decreasing the production of proinflammatory cytokines [28] . Dysregulated Cyp1a1 expression can also have a profound effect on the immune system in mice. Mice constitutively overexpressing Cyp1a1 had depleted AHR ligand levels, particularly at mucosal sites; acquired a quasi-AHR-deficient phenotype, characterized by low numbers of intestinal Th17 and group 3 innate lymphoid cells; and were highly susceptible to Citrobacterium rodentium infections [29] . This phenotype could be reversed by supplementing with dietary indoles-a source of AHR ligands-highlighting the importance of AHR ligand availability in regulating the gut immune responses.
Monocytes and macrophages play an important role in the recognition of microbes through sensing the presence of PAMPs (such as LPS) through PRRs (such as TLR4) and triggering an inflammatory response. Given the importance of AHR activation in regulating this inflammatory response, we sought to determine the profile of expression and the regulation of the AHR gene battery in monocytes and macrophages. We found that in primary human monocytes, concomitant stimulation with an AHR ligand (e.g., FICZ or KYN) and a TLR4 ligand (e.g., LPS) selectively suppressed the expression and function of CYP1 family members-paramount members of the AHR response-but not other genes of the AHR gene battery. Interestingly, this effect was most apparent in GM-CSF-differentiated macrophages. Such an effect was likely acquired during the differentiation of monocytes to macrophages under GM-CSF rather than a direct effect of GM-CSF stimulation. Our results reveal a novel regulatory step of AHR function that may determine the rate of AHR ligand metabolism and influence AHR functions during innate immune responses.
MATERIALS AND METHODS

Human cells
Human PBMCs were isolated from venous blood of healthy donors using Ficoll-Paque density centrifugation (GE Healthcare, Pittsburgh, PA, USA). All individuals gave their informed consent in compliance with the McGill University Ethics Review Board. Human primary monocytes were enriched (.90% purity) from PBMCs by negative-selection using the EasySep Human Monocyte Isolation Kit (Stemcell Technologies, Vancouver, BC, Canada). To obtain MDMs, monocytes were differentiated in 20 ng/ml M-CSF (M-MDM) or GM-CSF (GM-MDM). The phenotype of these cells has being characterized elsewhere [30] . All cells were cultured in HyClone RPMI 1640 (GE Healthcare), supplemented with 10% heat-inactivated FBS, sodium pyruvate, nonessential amino acids, L-glutamine, HEPES buffer (pH 8), and penicillin-streptamycin.
Reagents
CHX, Escherichia coli LPS, wortmannin, rapamycin, PD-184352, poly I:C, and staphylococcal PGN were purchased from Sigma-Aldrich (St. Louis, MO, USA). BIRB-0796, SB-203580, Bay 11-7082, and KYN were purchased from Cayman Chemical (Ann Arbor, MI, USA). R848, zymosan, depleted zymosan, PGN-SAndi, and CpG ODN2216 were purchased from InvivoGen (San Diego, CA, USA). Staphylococcus aureus strain S8 was isolated from the nostrils of a chronic carrier individual and cultured and prepared, as previously described [31] . FICZ was synthesized in-house, as previously described [32] .
Cytokine production
Human GM-MDMs (100,000 cells/well) were seeded in 96-well, round-bottom, tissue culture-treated plates, and stimulants were added at twice the desired concentration at a volume of 1:1. Cell-free supernatants were collected, and cytokine production was measured by ELISA (eBioscience, San Diego, CA, USA). When inhibitors were used, cells were pretreated for 1 h before stimulation. Unless indicated otherwise, DMSO (0.1%) was used as a vehicle control.
RT-qPCR
RNA from human monocytes (1 3 10 6 /group) was harvested using RNA Miniprep Super Kit (Bio Basic, Markham, ON, Canada) and reverse transcribed using the High-Capacity Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA). qPCR was performed using the SsoAdvanced SYBR Green Supermix kit (Bio-Rad Laboratories, Hercules, CA, USA) and run on a CFX96 (Bio-Rad Laboratories). Primers used in this study were designed using PrimerQuest (Integrated DNA Technologies, Coralville, IA, USA; Table 1 ). 
CYP1 activity
CYP1 activity was determined using the EROD assay, as described [17] . In brief, cells were stimulated, as indicated, in the respective figure legends, washed once in PBS containing 1 mM MgCl 2 and 1 mM CaCl 2 , resuspended in 150 ml 7-ethoxyresorufin (2 mM in PBS + 1 mM MgCl 2 + 1 mM CaCl 2 ), and incubated for 30 min at 37°C. Supernatants (100 ml) were then transferred to black fluorescent plates and stored at 220°C until read at 560/590 nm excitation/emission [33] on an EnSpire Plate Reader (PerkinElmer, Waltham, MA, USA). A standard curve of resorufin was used to determine the amount of resorufin produced. Following the EROD assay, cells were washed in PBS containing 1 mM MgCl 2 and 1 mM CaCl 2 and lysed in 25-50 ml radioimmunoprecipitation assay buffer to determine protein amount (bicinchoninic acid assay; Thermo Fisher Scientific). Data were plotted as picomolars of resorufin produced per milligram of protein.
Statistics
Statistical analysis was performed with GraphPad Prism 6, and P , 0.05 was deemed as significant.
RESULTS
PRR signaling inhibits the induction of Cyp1 family members by AHR ligands
AHR has recently been shown to be an effective regulator of proinflammatory cytokine production by monocytes and macrophages [25, 34] . However, the mechanisms of expression and regulation of the AHR gene battery in primary human monocytes and macrophages have not yet been explored. To investigate these mechanisms, we stimulated primary human monocytes isolated from venous blood of healthy donors with the AHR ligand FICZ alone or concomitantly, with the TLR4 ligand LPS or the gram-positive bacterium S. aureus, which principally signals through TLR2 [35] , and screened a panel of AHR gene-battery members for expression using RT-qPCR. As expected, AHR activation by FICZ led to a robust increase in the expression of the AHR response genes Cyp1a1, Cyp1b1, Ahrr, and Nqo1 (Fig.  1A-D ) but not other members tested (e.g., Cyp1a2, Fmo3, glutathione S-transferase U1, Nptx1, Serpine1, and Ugt1a6; data not shown). PRR signaling by itself, through TLR4 by LPS or through TLR2/NOD by S. aureus, did not induce AHR activation, although we observed mild activation of AHR genes, predominantly, Ahrr, in response to S. aureus in monocytes from some individuals. However, when primary human monocytes were stimulated concomitantly with both FICZ and LPS or S. aureus, we observed a significant decrease in the induction of Cyp1a1 and Cyp1b1 (Fig. 1A and B). Such an inhibition was not observed with the other two AHR gene-battery members, Ahrr and Nqo1 (Fig. 1C and D) , implying that the inhibition of AHR activation was selective for the Cyp1 family genes.
To verify this finding, we performed an extensive dose titration of both FICZ (0.01-100 nM) and LPS (0.01-1 ng/ml) on primary human monocytes and assessed Cyp1a1 and Ahrr mRNA levels. We observed that LPS inhibited the induction of Cyp1a1 by FICZ across all concentrations tested in a dose-dependent manner, whereas as expected, Ahrr was not suppressed by any LPS concentration tested (Fig. 1E ). This inhibition was not unique to FICZ, as a similar down-regulation of Cyp1a1 was also observed in response to KYN (Fig. 1F) , an AHR ligand generated from tryptophan catabolism that is increased during systemic infections [25] . Based on these results, we concluded that TLR4 and TLR2 signaling selectively regulate the induction of the Cyp1 family by AHR activation.
We next investigated if this selective down-regulation of the Cyp1 members upon AHR activation was unique to TLR4 and TLR2 signaling or was applicable to other PRR signaling. To do this, we tested the Cyp1a1 regulatory capacity of E. coli LPS (TLR4 ligand), staphylococcal PGN (TLR2 and NOD1/2 ligands), ultrapure PGN-SAndi (NOD1/2 ligand), zymosan (TLR2 and dectin-1 ligands), depleted zymosan (dectin-1 ligand), poly I:C (TLR3 ligand), R848 (TLR8 ligand), and CpG ODN2216 (TLR9 ligand). We found that all PAMPs tested were able to inhibit significantly the induction of Cyp1a1 by FICZ (Fig. 2) . Thus, down-regulation of the Cyp1 family members by PRR signaling upon AHR activation is likely applicable to all PRRs.
We next examined the mechanism by which PRR signaling down-regulates Cyp1 family induction by AHR. It has previously been reported that proinflammatory cytokines, such as IL-1b and TNF-a, can inhibit TCDD-induced Cyp1a1 expression in hepatocytes [36, 37] . To assess if cytokine production in response to PRR signaling was required for PRR-mediated down-regulation of Cyp1, we blocked cytokine production by inhibiting protein translation with CHX and assessed if LPS was still able to suppress Cyp1a1 induction. Similar to a previous report [38] , CHX superinduced Cyp1a1 expression, with and without FICZ stimulation (Fig. 3A) . However, even in the presence of CHX, where cytokine protein production would not occur, LPS was still able to suppress Cyp1a1 induction to a proportionally similar extent, as in the absence of CHX. Interestingly, LPS was also able to block, in part, the superinducing effects of CHX on Cyp1a1 expression. This result suggests that protein synthesis and therefore, de novo cytokine production is not required for the down-regulation of Cyp1 by PRRs.
As CHX treatment did not prevent Cyp1 down-regulation by LPS, we hypothesized that PRR signaling was directly blocking Cyp1 induction by AHR activation. PRRs signal through 3 major pathways: PI3K-Akt-mTOR, MAPK, and NF-kB [39] . To identify which of these pathways was required for Cyp1 inhibition, we used small molecules that specifically target each pathway [40] . We first assessed the PI3K-Akt-mTOR pathways using the pan-PI3K inhibitor wortmannin and the mTOR inhibitor rapamycin (Fig.  3B) . We observed that PI3K-Akt-mTOR inhibition significantly reduced Cyp1a1, but not Ahrr, induction by FICZ. However, neither inhibitor reversed the down-regulatory effects of LPS on Cyp1a1 expression. Next, we blocked the MAPK p38 using SB-203580 or BIRB-0796 (Fig. 3C) . Again, we observed no effect on LPS-mediated down-regulation of Cyp1a1, but we did find a significant reduction in Cyp1a1 and Ahrr induction by FICZ, perhaps by regulating AHR nuclear localization [41, 42] . Moreover, the blocking of ERK-MAPK signaling using PD-184352 also failed to reverse the effect of LPS stimulation on Cyp1a1 expression or to block induction of the AHR gene battery by FICZ (Fig. 3D) . Lastly, we blocked the NF-kB using BAY 11-7082. However, BAY 11-7082 completely prevented the up-regulation of the Cyp1a1 and Ahrr by FICZ, precluding our ability to assess whether LPS stimulation could down-regulate the expression of Cyp1a1 (Fig. 3E) . Collectively, these results suggest that PRRs likely regulate Cyp1 induction through mechanisms different from the PI3K-Akt and the p38 and ERK-MAPK pathways, A broad range of PAMPs suppresses Cyp1a1 induction by FICZ in primary human monocytes. Cyp1a1 RNA expression in human monocytes stimulated with FICZ and various PAMPs for 6 h, as measured by RT-qPCR. PGN (10 mg/ml); SAndi (10 mg/ml); zymosan (Zym; 10 mg/ml); depleted zymosan (D-Zym; 10 mg/ml); poly I:C (PIC; 10 mg/ml); R848 (10 mg/ml); and CpG ODN2216 (1 mM). Data are plotted as mean 6 SEM of 3 independent experiments from 3 different donors, each performed in duplicates. *P , 0.05; **P , 0.01; ***P , 0.001. leaving open the possibility that it is through activation of the NF-kB pathway.
Selective suppression of the CYP1 members by PAMPs is most apparent in GM-CSF-differentiated MDMs
We next wanted to corroborate our findings by investigating if the suppression of the Cyp1 family by PAMPs translated into reduced enzymatic activity of CYP1. To test this, we stimulated human primary monocytes with FICZ and/or LPS for 24 h and assayed for CYP1 activity using the EROD assay. In primary human monocytes, the levels of CYP1 activity upon FICZ stimulation were below the sensitivity of the assay (Fig. 4A) . During an infection, monocytes migrate to inflamed tissues and differentiate into macrophages, playing important roles in cytokine production, pathogen clearance, and resolution of inflammation [43, 44] . Therefore, we asked if MDMs expressed CYP1. In vitro, monocytes can be differentiated into macrophages using GM-CSF (GM-MDMs) or M-CSF (M-MDMs). GM-MDMs have a more proinflammatory M1 macrophage phenotype (e.g., classically activated macrophages), whereas M-MDMs are more of an antiinflammatory M2-type macrophage (e.g., alternatively activated macrophages) [30] . When we stimulated MDMs for 24 h with FICZ, we found an increase in CYP1 activity in GM-MDMs, whereas the CYP1 activity in M-MDM remained unchanged (Fig. 4B) . Importantly, in GM-MDMs, concomitant stimulation with FICZ and LPS led to a significant reduction of CYP1 activity compared with FICZ stimulation alone, corroborating what was observed at the mRNA level in monocytes. The induction of CYP1 activity in macrophages, particularly in GM-MDM, was not the result of direct up-regulation of CYP1 activity by GM-CSF but was a result of the differentiation state of the macrophages. This was illustrated by the observations that a 1 h pretreatment with GM-CSF did not induce CYP1 activity in human primary monocytes in resting conditions or after FICZ or LPS stimulation (Fig. 5A) and by the minimal effect of GM-CSF once MDMs had been generated in the presence of M-CSF (Fig.  5B) . Importantly, in all conditions, LPS significantly inhibited CYP1 activity induced by FICZ (Fig. 5B) . Collectively, these data suggest that GM-CSF cannot directly drive CYP1 expression but rather, differentiates monocytes into macrophages that express CYP1 protein upon AHR activation and that LPS can inhibit this expression.
AHR activation regulates the proinflammatory cytokine response of GM-CSF-differentiated MDMs
Given the selective down-regulation of Cyp1 members in the AHR gene battery by PRR signaling, we tested the effect of AHR activation on PRR-induced cytokine production by GM-MDMs. This was important, as the AHR pathway has been linked to LPS tolerance and inhibition of proinflammatory responses [22] . So, we stimulated GM-MDMs with LPS alone or in combination with the AHR ligand FICZ and determined the production of proinflammatory cytokines and chemokines and of the antiinflammatory cytokine IL-10. We found that the secretion of the proinflammatory cytokine IL-6 ( Fig. 6A ) and chemokine CCL3 (Fig. 6B) was reduced significantly by AHR activation but that the production of the anti-inflammatory cytokine IL-10 was not affected (Fig. 6C) . In human moDCs, AHR has been reported to enhance the production of IL-1b and IL-8 [45] , contrary to its inhibitory effect on other proinflammatory cytokines [34] . Although we were unable to detect significant production of IL-1b in GM-MDMs (data not shown), we too found that AHR activation by FICZ significantly enhanced the production of IL-8 in GM-MDMs stimulated with LPS (Fig. 6D) .
DISCUSSION
It is now well established that the AHR is an effective regulator of the immune system [19] . In particular, it has been shown that AHR activation can influence the differentiation and function of Th17 [20, 21, 46] and type 1 T regs [47] and suppress the production of inflammatory cytokines in monocytes and macrophages [22] . These AHR functions have been associated with its ability to interact directly with known transcription factors of the immune system (e.g., NF-kB [22] , c-Maf [47] , and retinoic acid receptor-related orphan receptor gt [48] ). However, the expression and functional implications of classic AHR genebattery members in the immune system are understudied. Similar to what is observed in the liver by inflammatory stimuli [49] [50] [51] , we report that PRR signaling can selectively inhibit the induction of the Cyp1 family by AHR ligands in primary human monocytes and macrophages. This could potentially lead to enhanced AHR activation by decreasing the metabolism of AHR ligands through CYP1. Such a claim is consistent with the previous observation that pharmacological inhibition of CYP1 augments and prolongs AHR activation [17] . Therefore, the down-regulation of the Cyp1 family by PAMPs may function as a feedback mechanism to weaken the inflammatory response in monocytes and macrophages by enhancing AHR activation.
When monocytes egress from the blood and enter into peripheral tissues, they differentiate into macrophages or DCs [43, 44] . In vitro, human monocytes can be differentiated into macrophages using M-CSF or GM-CSF [30] . M-CSF is constitutively expressed in vivo and regulates macrophage functions during homeostasis, whereas GM-CSF is produced in a variety of infections and chronic inflammatory conditions and is a potent activator of inflammatory responses in macrophages [52] . Interestingly, we were only able to observe substantial CYP1 activity in GM-CSF-derived macrophages. These macrophages are much more proinflammatory than their M-CSF-derived counterparts, and the enhanced activity of CYP1 may serve as a mechanism to help regulate this phenotype. The molecular mechanisms of how GM-CSF induces CYP1 activity in macrophages are unknown.
GM-CSF was unable to increase CYP1 activity in monocytes, and continuous exposure to GM-CSF was required for full CYP1 activity in GM-CSF-derived macrophages. Moreover, we observed a slight increase in CYP1 activity in M-CSF-derived macrophages treated with GM-CSF for 2 d. Therefore, our data suggest that GM-CSF primes human macrophages for CYP1 protein expression following AHR activation and that persistent GM-CSF exposure is required to maintain this expression in differentiated macrophages.
Monocytes can also differentiate into DCs during inflammation and tissue infiltration [53] . A recent study found that LPS stimulation in human moDCs augmented the expression of AHR and enhanced the induction of Cyp1a1 by the AHR ligand TCDD [54] . With the use of U927-derived DCs, the authors determined that LPS caused NF-kB binding to the promoter of Ahr and transactivation of the Ahr gene. Interestingly, we did not observe the same effect in human monocytes or MDMs. To the contrary, our data showed that LPS could not induce Ahr expression (data not shown) and that AHR-dependent Cyp1a1 induction was inhibited in these cells. However, similar to what has been reported in moDCs [45] , we also observed that AHR antagonized some proinflammatory cytokines (e.g., IL-6, CCL3) but enhanced the production of others (e.g., IL-8). Likewise, AHR activation increased the expression of IL-23 in M-CSFderived macrophages [55] . Therefore, it appears that the effects of AHR on PRR-induced cytokine production by myeloid cells may be more complex than what was originally reported [22, 23] . Further work is required to understand fully the discrepancies and similarities in AHR-NF-kB interactions among monocytes, MDMs, and moDCs and their implications in vivo.
PRRs activate several signaling pathways upon ligand binding, including NF-kB, MAPK, and PI3K-Akt-mTOR (Fig. 3B, C , and E). With the use of pathway-specific small-molecule inhibitors [40] , we found that the PI3K-Akt-mTOR and p38 and ERKMAPKs signaling pathways were dispensable for Cyp1 downregulation by PAMPs. In addition, we found that the blocking of NF-kB signaling with Bay 11-7082 resulted in the complete suppression of AHR gene-battery induction by FICZ and that this could not be reduced further by LPS. Although not entire conclusive, these data suggest that NF-kB signaling could be responsible for the down-regulation of Cyp1 by PAMPs. This is supported by a previous study showing that overexpression of NF-kB in a hepatocyte cell line blocked TCDD-induced AHR activation [36] . Binding interactions between AHR and NF-kB have also been reported [22, 56, 57] . These studies have uncovered a function for AHR in regulating NF-kB-dependent responses to LPS, such as inhibition of IL-6 production [22] . Our data extend this model to include AHR-dependent genes and suggest that the AHR-NF-kB interaction in monocytes and macrophages is a mutually inhibitory event that suppresses both AHR-dependent genes (e.g., Cyp1a1, Cyp1a2) and NF-kBdependent genes (e.g., IL-6, CCL3, etc.). Why this interaction does not affect other AHR gene-battery members, e.g., Ahrr or Nqo1, remains unclear. One possibility is that some of these genes, such as Ahrr [58] , contain an NF-kB-binding site in their promoter. In these cases, the ability of AHR or NF-kB to activate the gene transcriptionally may supersede the inhibitory mechanism. Important for this model, the AHR-NF-kB-binding interaction does not prevent the DNA-binding capacity of each other [22, 37] .
Our experiments show that AHR is regulated by signaling pathways used by PRRs, even in the absence of exogenous activation of these receptors. Specifically, we found that inhibitors of the p38, PI3K-Akt-mTOR, and NF-kB pathways significantly decreased the induction of Cyp1a1 and Ahrr by FICZ. Although we cannot completely rule out off-target effects of these inhibitors on AHR signaling, we think this is an unlikely explanation for two reasons. First, although most of the inhibitors used contain ring-like chemical structures, none of them contain the successive polyaromatic rings seen in conventional AHR ligands, such as TCDD and FICZ. Moreover, the two p38 inhibitors used in this study (BIRB-0796 and SB-203580) have substantially different chemical structures, but both were able to decrease Cyp1a1 induction by FICZ. Second, wortmannin [59] and rapamycin [60] have previously been used in other cells types without reducing the transcriptional activity of AHR. In fact, in a hepatocyte luciferase-reporter cell line, rapamycin augmented AHR activation by TCDD [60] . Therefore, it is more plausible that these signaling cascades can regulate AHR function. It has already been established that p38 regulates AHR nuclear localization by phosphorylating Ser68, in its NES [41, 42, 61] , preventing CRM1 recognition of the NES and blocking subsequent nuclear export, with the net effect of increased nuclear accumulation of AHR. How PI3K-Akt-mTOR and NF-kB signaling regulates AHR signaling is not known. Collectively, these pathways may function to promote AHR activation in an attempt to counterbalance the inflammatory response induced by PAMPs.
In conclusion, our work reveals a mechanism of PRR signaling in regulating AHR-dependent responses in human monocytes and macrophages. This mechanism is selective for the Cyp1 family and likely evolved as a mechanism to limit hyperinflammatory states, such as sepsis. Future studies should explore the molecular mechanisms that are required for this inhibition to identify novel therapeutic targets for hyperinflammatory disorders.
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